Bienaime Jean Jacques's Form 4 filing
Biomarin Pharmaceutical Inc (BMRN) · filed Dec 17, 2021
- Accession no.
- 0001567619-21-022297
- Filed
- Dec 17, 2021
- Trade date
- Dec 10-16, 2021
- Filing delay
- 7 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.00M. It was filed 7 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bienaime Jean JacquesCIK 0001221590 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 10, 2021 | Common Stock | GGiftDisposed | −700 | $0.00 | $0 | 303,689 | Direct | |
| Dec 15, 2021 | Common Stock | MOption exerciseAcquired | +6,000 | $37.46 | +$224,760 | 309,689 | Direct | |
| Dec 15, 2021 | Common Stock | SSaleDisposed | −6,000 | $82.71 | −$496,260 | 303,689 | Direct | |
| Dec 16, 2021 | Common Stock | MOption exerciseAcquired | +6,000 | $37.46 | +$224,760 | 309,689 | Direct | |
| Dec 16, 2021 | Common Stock | SSaleDisposed | −6,000 | $84.68 | −$508,080 | 303,689 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2021 | Common Stock | MOption exerciseDisposed | −6,000 | $0.00 | $0 | 131,000 | Direct | |
| Dec 16, 2021 | Common Stock | MOption exerciseDisposed | −6,000 | $0.00 | $0 | 125,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.